Clinical Trial Update: ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment [Phase 2]

View source ↗

Summary

The ARTDeCo Phase 2 study of RO4995819 in adults with major depressive disorder who have inadequate response to ongoing antidepressant treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• RO4995819

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED